Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up

Abstract

We examined factors associated with hospital admissions and bed stay for 211 patients prescribed risperidone long-acting injection (RLAI) in clinical practice. Hospital bed days increased by a median of 74 days in the 3 years after RLAI initiation compared with the 3 years before initiation (P < 0.0001). Only subjects starting RLAI as outpatients showed no increase in bed days after RLAI initiation. A greater than expected number of bed days was observed in women (36% increase), patients prescribed >25 mg/2 weeks (70% increase) and patients previously treated with clozapine (118% increase). Overall, number of hospital admissions did not increase, although those previously prescribed clozapine saw a 31% increase in admissions compared with patients not previously exposed to clozapine. This and other analyses of the same patient cohort indicate that RLAI produces most favourable outcomes in outpatients and those not previously treated with clozapine.

Keywords

bed stay depot hospital naturalistic risperidone

References

Bai, YM , Chen, TT , Wu, B. , Hung, CH , Lin, WK , Hu, TM , et al. (2006) A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 39: 135-141.

Ezewuzie, N. , Taylor, D. ( 2006) Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 20: 86-90.

Gefvert, O. , Eriksson, B. , Persson, P. , Helldin, L. , Bjorner, A. , Mannaert, E. , et al. (2005) Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal ConstaTM) in patients with schizophrenia. Int J Neuropsychopharmacol 8: 27-36.

Kane, JM , Eerdekens, M. , Lindenmayer, JP , Keith, SJ , Lesem, M. , Karcher, K. ( 2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132.

Keks, NA , Ingham, M. , Khan, A. , Karcher, K. ( 2007) Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 191: 131-139.

Lin, KM , Poland, RE , Nuccio, I. , Matsuda, K. , Hathuc, N. , Su, TP , et al. (1989) A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients . Am J Psychiatry 146: 1307-1311.

Nesvag, R. , Hendset, M. , Refsum, H. , Tanum, L. ( 2006) Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 114: 21-26.

Niaz, OS , Haddad, PM ( 2007) Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 116: 36-46.

Taylor, D. ( 2006) Risperidone long-acting injection in practice - more questions than answers? Acta Psychiatr Scand 114: 1-2.

10.

Taylor, D. , Fischetti, C. , Sparshatt, A. , Thomas, A. , Bishara, D. , Cornelius, V. (2009a) Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 120 : 97 -101.

11.

Taylor, D. , Fischetti, C. , Sparshatt, A. , Thomas, A. , Bishara, D. , Cornelius, V. (2009b) Risperidone long-acting injection: a prospective 3 year analysis of its use in clinical practice. J Clin Psychiatry 70: 196-200.

12.

Taylor, DM , Young, C. , Patel, MX ( 2006) Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 9: 685-694.

13.

Young, CL , Taylor, DM ( 2006) Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 114: 14-20.